Do you want to read an article? Please log in or register.
Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma
Asthma
Related content
Asthma
Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma
Adv Ther.
Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E
doi: 10.1007/s12325-019-01191-2.
RECOMMENDED
Asthma
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
Lancet Respir Med.
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators
doi: 10.1016/S2213-2600
Asthma
The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies
Curr Med Res Opin.
Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X
doi: 10.1080/
RECOMMENDED
Asthma
Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma
Clin Pharmacol Ther.
Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L
doi: 10.1002/cpt.
RECOMMENDED
Asthma
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
Eur Respir J.
Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG
doi: 10.1183/13993003.
Asthma
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Lancet.
Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M; SIROCCO study investigators
doi: 10.1016/
RECOMMENDED
ARDSAsthma
Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Allergy Clin Immunol Pract.
Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, Harel S, Jagerschmidt A, Khan A, Kamat S, Maroni J, Rowe P, Lu Y, Amin N, Pirozzi G, Ruddy M, Graham NMH, Teper A
doi: 10.1016/j.jaip.2019.08.050.
Asthma
Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
Lancet Respir Med.
FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M
doi: 10.1016/
RECOMMENDED
Asthma
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Respir Med.
Bagnasco D, Brussino L, Bonavia M, Calzolari E, Caminati M, Caruso C, D'Amato M, De Ferrari L, Di Marco F, Imeri G, Di Bona D, Gilardenghi A, Guida G, Lombardi C, Milanese M, Nicolini A, Riccio AM, Rolla G, Santus P, Senna G, Passalacqua G
doi: 10.1016/j.rmed.2020.106080.